Related Experiment Video
Updated: Jan 30, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
S N Batskikh1, E V Vinnitskaya1, Yu G Sandler1
1A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health, Moscow, Russia.
Abstract:
Today, there is no complete clarity about the pathogenetic mechanisms of the hepatic decompensation in patients with HCV-cirrhosis during the course of direct-acting antiviral (DAAs) therapy. The current article describes several clinical observations of decompensation (with the development of liver failure and portal hypertension) in cirrhotic patients during the course of DAAs-therapy of hepatitis C. The authors present contemporary views and their own assumptions about the possible mechanisms of the hepatic decompensation associated with DAAs-therapy in patients with liver cirrhosis.
Related Concept Videos
The Antiviral System of Bacteria and Archaea: CRISPR
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Gene Therapy
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Group Therapy

